Wall Street Zen Upgrades Eli Lilly to Strong-Buy

Analysts cite the pharmaceutical company's robust financial performance and promising pipeline.

Published on Mar. 8, 2026

Got story updates? Submit your updates here. ›

Wall Street Zen has upgraded its rating on shares of Eli Lilly and Company (NYSE:LLY) from a 'buy' to a 'strong-buy' in a research report sent to investors. The upgrade comes as Eli Lilly has seen strong financial results, with the company reporting earnings per share of $7.54 in its most recent quarter, exceeding analyst estimates. Wall Street Zen and other analysts have also cited Eli Lilly's promising drug pipeline as a key factor driving the positive outlook.

Why it matters

Eli Lilly is one of the world's leading pharmaceutical companies, with a diverse portfolio of medicines and a robust research and development pipeline. The strong 'strong-buy' rating from Wall Street Zen reflects growing confidence in the company's ability to deliver continued growth and innovation, which could have positive implications for investors as well as patients who rely on Eli Lilly's therapies.

The details

In its research report, Wall Street Zen highlighted Eli Lilly's recent financial performance, noting that the company reported earnings per share of $7.54 in its most recent quarter, exceeding the consensus analyst estimate of $7.48. The report also cited Eli Lilly's promising drug pipeline, including several late-stage candidates in development for a range of therapeutic areas. Other analysts, such as those from Jefferies Financial Group and Daiwa Securities Group, have also issued positive ratings and price targets for Eli Lilly's stock.

  • Eli Lilly reported its most recent quarterly earnings on February 4, 2026.
  • Wall Street Zen issued its research report and upgraded Eli Lilly's rating on March 8, 2026.

The players

Eli Lilly and Company

A global pharmaceutical company founded in 1876 and headquartered in Indianapolis, Indiana. Eli Lilly researches, develops, manufactures, and commercializes a broad range of medicines and therapies for patients worldwide.

Wall Street Zen

A financial research and analysis firm that provides investment recommendations and insights to investors.

David A.

The President and Chief Executive Officer of Eli Lilly and Company.

Got photos? Submit your photos here. ›

What they’re saying

“We must not let individuals continue to damage private property in San Francisco.”

— Robert Jenkins, San Francisco resident (San Francisco Chronicle)

“Fifty years is such an accomplishment in San Francisco, especially with the way the city has changed over the years.”

— Gordon Edgar, grocery employee (Instagram)

What’s next

The judge in the case will decide on Tuesday whether or not to allow Walker Reed Quinn out on bail.

The takeaway

This case highlights growing concerns in the community about repeat offenders released on bail, raising questions about bail reform, public safety on SF streets, and if any special laws to govern autonomous vehicles in residential and commercial areas.